Infusion of lipoproteins into volunteers enhances the growth of Candida albicans

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1148-1151

  Netea, Mihai G ^a   Curfs, Jo H A J ^a   Demacker, Pierre N M ^a   Meis, Jacques F G M ^a   Van Der Meer, Jos W M ^a   Kullberg, Bart Jan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; VERY LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; FUNGUS GROWTH; HUMAN; HUMAN EXPERIMENT; HYPERLIPOPROTEINEMIA; IN VITRO STUDY; MOUSE; NONHUMAN; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; SEPSIS; TREATMENT CONTRAINDICATION;

EID: 0032962596     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514757     Document Type: Article

References (16)

1. 1. Parillo JE, Parker MM, Natanson C, et al. Septic shock in humans: advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990; 113:227-42.
2. 2. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-1 containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circulatory Shock 1993; 40:14-23.
3. 3. Hubsch AP, Casas AT, Doran JE. Protective effects of reconstituted high-density lipoprotein in rabbit gram-negative bacteremia models. J Lab Clin Med 1995; 126:548-58.
4. 4. Pajkrt D, Doran JE, Koster F, et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996; 184:1601-8.
5. 5. Fischer-Hoch SP, Hutwagner L. Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995; 21:897-904.
6. 6. Netea MG, Demacker PNM, De Bont N, et al. Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice. Infect Immun 1997; 65:2663-7.
7. 7. Melly MA, Meng HC, Schaffner W. Microbial growth in lipid emulsions used in parenteral nutrition. Arch Surg 1975; 110:1479-81.
8. 8. Mershon J, Nogami W, Williams JM, Yoder C, Eitzen HE, Lemons JA. Bacterial/fungal growth in a combined parenteral nutrition solution. JPEN J Parenter Enteral Nutr 1986; 10:498-502.
9. 9. D'Angio R, Quercia RA, Treiber NK, McLaughlin JC, Klimek JJ. The growth of microorganisms in total parenteral nutrition admixtures. JPEN J Parenter Enteral Nutr 1987; 11:394-7.
10. 10. Demacker PN, van Sommeren-Zondag DF, Stalenhoef AF, Stuyt PM, van't Laar A. Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3. Clin Chem 1983; 29:656-63.
11. 11. Netea MG, Demacker PNM, Kullberg BJ, et al. Low-density-lipoprotein receptor deficient mice are protected against lethal endotoxinemia and severe gram-negative infections. J Clin Invest 1996; 97:1366-72.
12. 12. Shine WE, Silvany R, McCulley JP. Relation of cholesterol-stimulated Staphylococcus aureus growth Io chronic blepharitis. Invest Ophthalmol Vis Sci 1993; 34:2291-6.
13. 13. Payne CD, Ray TL, Downing DT. Cholesterol sulfate protects Candida albicans from inhibition by sphingosine in vitro. J Invest Dermatol 1996; 106:549-52.
14. 14. Yeaman MR, Ibrahim AS, Edwards JE Jr, Bayer AS, Ghannoum MA. Thrombin-induced rabbit platelet microbicidal protein is fungicidal in vitro. Antimicrob Agents Chemother 1993; 37:546-53.
15. 15. Murthy ARK, Lehrer RI, Harwig SSL, Miyasaki KT. In vitro candidastatic properties of the human neutrophil calprotectin complex. J Immunol 1993; 151:6291-301.
16. 16. Tada N, Sakamoto K, Kagami A, Mochizuki K, Kurosaka K. Antimicrobial activity of lipoprotein particles containing apolipoprotein Al. Mol Cell Biochem 1993; 119:171-8.